相关实验视频
Updated: Jul 5, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
对急性缺血性脑卒中血栓溶解的 Tenecteplase:实际考虑和现实世界的实施
1University of Minnesota, Minneapolis.
Neurology. Clinical practice
|January 15, 2024
概括
甲作为急性缺血性中风 (AIS) 的纤维解药物表现有前途,可能与甲的疗效相匹配. 本综述考察了证据,非标签使用,以及在中风护理中转换为tenecteplase的实际考虑.
科学领域:
- 神经学 神经学
- 紧急医疗 紧急医疗
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔特普拉斯是FDA唯一批准的急性缺血性中风 (AIS) 治疗方法.
- 一种较新的纤维解毒剂Tenecteplase由于临床试验数据,工作流效率和成本效益而获得了吸引力.
- 医学界正在评估基在AIS血栓溶解中的作用.
研究的目的:
- 综合当前的证据,比较AIS的tenecteplase和alteplase.
- 讨论非标签使用的烯酸替代剂的含义.
- 概述从alteplase过渡到tenecteplase的实际考虑.
主要方法:
- 审查当前的临床试验证据.
- 讨论机构在使用基替代剂方面的经验.
- 对治疗考虑因素,非标签使用,同意,认证和成本的分析.
- 详细说明工作流程的修改,以确保安全过渡.
主要成果:
- 目前正在评估证据,以确定基的非劣势性或优势性.
- 非标签使用及其后果正在接受审查.
- 详细介绍了中风护理协议过渡的实际方面.
结论:
- 甲呈现了一个可行的替代品Alteplase用于AIS血栓溶解.
- 仔细考虑证据,非标签使用和工作流程集成是必不可少的.
- 过渡到tenecteplase需要战略规划,以确保安全有效的实施.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K

